Home LiteratureArticle Details
PMID: 16799337 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma.

Journal of immunotherapy (Hagerstown, Md. : 1997) ·Vol. 29 ·No. 4 ·2006-00-00 ·Pages 416-24

Liyanage UK, Goedegebuure PS, Moore TT, Viehl CT, Moo-Young TA, Larson JW, Frey DM, Ehlers JP, Eberlein TJ, Linehan DC

Abstract

We reported earlier that patients with breast or pancreas cancer have an increased prevalence of regulatory T cells (Treg) in the blood and tumor draining lymph nodes (TDLNs) compared with healthy individuals. In the current study, we tested the hypothesis that tumor cells promote the prevalence of Treg. The transforming growth factor-beta (TGF-beta) secreting murine pancreas adenocarcinoma, Pan02 cell line was injected into syngeneic C57BL/6 mice and the prevalence of Treg in the TDLNs and tumor spleen was measured weekly. Compared with control mice, the prevalence of CD25+ CD4+ cells in TDLNs and in tumor spleen increased with tumor growth. Analysis of these CD25+ CD4+ T cells in vitro confirmed expression of the Treg marker, Foxp3. In addition, their functional activity resembled that of Treg, as evidenced by a poor proliferative capacity; suppression of proliferation of CD25- CD4 or CD8T cells and inhibition of interferon-gamma release by CD25- CD4+ T cells. Reconstitution of Pan02-bearing Rag-/- mice with naive syngeneic CD25- CD4+ T cells induced CD25+ CD4+ Foxp3+ T cells in TDLNs, but not in the spleen. In contrast, Foxp3 was not detected in unreconstituted Pan02-bearing Rag-/- mice, or reconstituted mice bearing a TGF-beta-negative esophageal tumor. Furthermore, administration of neutralizing anti-TGF-beta antibody blocked the induction of Foxp3 in reconstituted Pan02-bearing Rag-/- mice. These results mimic earlier in vitro studies showing induction of Foxp3 through CD3 plus CD28 stimulation in the presence of TGF-beta. We conclude that Pan02 tumor promotes the prevalence of Treg, in part through the secretion of TGF-beta, which may result in immune evasion.

MeSH Terms
Adenocarcinoma/immunology,pathology Animals CD4-Positive T-Lymphocytes/metabolism Cell Line, Tumor Forkhead Transcription Factors/genetics Gene Expression/drug effects Lymph Nodes/cytology Lymphocyte Count Mice Mice, Inbred C57BL Pancreatic Neoplasms/immunology,pathology Phenotype RNA, Messenger/metabolism Receptors, Interleukin-2/blood Spleen/cytology T-Lymphocytes/immunology T-Lymphocytes, Regulatory/cytology,immunology Transforming Growth Factor beta/pharmacology
Chemicals
Forkhead Transcription Factors Foxp3 protein, mouse RNA, Messenger Receptors, Interleukin-2 Transforming Growth Factor beta
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Liyanage Udaya K
Laboratory for Biologic Cancer Therapy, Department of Surgery and Alvin J. Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO, USA.
Goedegebuure Peter S
Moore Todd T
Viehl Carsten T
Moo-Young Tricia A
Larson Justin W
Frey Daniel M
Ehlers Jesmin P
Eberlein Timothy J
Linehan David C
Article Info
Journal
Journal of immunotherapy (Hagerstown, Md. : 1997)
Abbr.
J Immunother
ISSN
1524-9557
Published
2006-00-00
Pages
416-24
Language
English
Region
United States
NLM ID
9706083
Subset
IM
Grants
NCI NIH HHS · T32 CA009621 · United States
NCI NIH HHS · K08 CA87018-01 · United States
NCI NIH HHS · T32 CA09621-11 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]